London-based Apoha has raised $36M led by Singular to commercialise a platform that measures how molecules and materials actually behave, a data class that has never existed at scale before.
Founded by husband-and-wife duo Shamit Shrivastava and Anshika Srivastava, the company is already used by Boehringer Ingelheim to identify high-risk antibody candidates with greater than 90% precision from just 8 micrograms of material.
The global biophysical assays market stands at $3.8B in 2025 and is projected to reach $7.9B by 2034, growing at a CAGR of 8.5%, according to Dataintelo.
AI has learned to read language, interpret images, and write code. It still cannot feel matter. That gap, the absence of structured, empirical data about how molecules and materials actually behave under real-world conditions, costs the pharmaceutical industry billions every year in late-stage clinical trial failures. Apoha was built to close it. And behind it is one of the more unusual founding stories in London’s deep science scene: a husband and wife, one an Oxford physicist with 15 years of foundational research, the other a Goldman Sachs Executive Director who left one of the world’s most powerful financial institutions to help turn that research into a commercial platform.
